# Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease

> **NCT03459079** · PHASE2 · COMPLETED · sponsor: **University of Florida** · enrollment: 128 (actual)

## Conditions studied

- Nonalcoholic Fatty Liver Disease (NAFLD)
- Type 2 Diabetes (T2DM)

## Interventions

- **DRUG:** Lanifibranor
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03459079
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-14
- **Primary completion:** 2023-04-18
- **Final completion:** 2023-06-01
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03459079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03459079, "Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03459079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*